Related Experiment Video
Updated: Apr 15, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2
Xuesong Li1, Xuhai Gong1, Jing Chen2
1Department of Neurology, Daqing Oilfield General Hospital, Daqing, Heilongjiang 163001, China.
Abstract:
Glioblastoma development is often associated with alteration in the activity and expression of cell cycle regulators, such as cyclin-dependent kinases (CKDs) and cyclins, resulting in aberrant cell proliferation. Recent studies have highlighted the pivotal roles of miRNAs in controlling the development and growth of glioblastoma. Here, we provide evidence for a function of miR-340 in the inhibition of glioblastoma cell proliferation. We found that miR-340 is downregulated in human glioblastoma tissue samples and several established glioblastoma cell lines. Proliferation and neurosphere formation assays revealed that miR-340 plays an oncosuppressive role in glioblastoma, and that its ectopic expression causes significant defect in glioblastoma cell growth. Further, using bioinformatics, luciferase assay and western blot, we found that miR-340 specifically targets the 3'UTRs of CDK6, cyclin-D1 and cyclin-D2, leading to the arrest of glioblastoma cells in the G0/G1 cell cycle phase. Confirming these results, we found that re-introducing CDK6, cyclin-D1 or cyclin-D2 expression partially, but significantly, rescues cells from the suppression of cell proliferation and cell cycle arrest mediated by miR-340. Collectively, our results demonstrate that miR-340 plays a tumor-suppressive role in glioblastoma and may be useful as a diagnostic biomarker and/or a therapeutic avenue for glioblastoma.
Insights
MicroRNA-340 (miR-340) suppresses glioblastoma growth by targeting cell cycle regulators like CDK6. Its downregulation in tumors suggests miR-340 as a potential glioblastoma biomarker and therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Glioblastoma (GBM) progression involves dysregulated cell cycle control, with altered expression of cyclin-dependent kinases (CDKs) and cyclins.
- MicroRNAs (miRNAs) are increasingly recognized as key regulators in glioblastoma development and growth.
Purpose of the Study:
- To investigate the role of miR-340 in glioblastoma proliferation and its potential as an oncosuppressive agent.
Main Methods:
- Analysis of miR-340 expression in human glioblastoma tissues and cell lines.
- In vitro assays including proliferation, neurosphere formation, bioinformatics, luciferase assays, and Western blot.
- Assessment of cell cycle phase distribution and rescue experiments.
Main Results:
- miR-340 was found to be significantly downregulated in glioblastoma samples and cell lines.
- Ectopic expression of miR-340 inhibited glioblastoma cell proliferation and neurosphere formation.
- miR-340 directly targets the 3'UTRs of CDK6, cyclin-D1, and cyclin-D2, leading to G0/G1 cell cycle arrest.
- Restoration of CDK6, cyclin-D1, or cyclin-D2 partially rescued cells from miR-340-mediated growth suppression.
Conclusions:
- miR-340 functions as a tumor suppressor in glioblastoma by inhibiting cell proliferation through targeting cell cycle regulators.
- miR-340 holds promise as a diagnostic biomarker and a potential therapeutic strategy for glioblastoma.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
MicroRNAs
MicroRNAs
Negative Regulator Molecules
Mitogens and the Cell Cycle

